Xenon shares fall following depression trial pause

Published 18 Sep 2026, 16:09 UTC. Updated 21 Sep 2026, 19:09 UTC.

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

Directly affected

No company is named in this report.

Indirectly affected

NAMS NEW AMSTERDAM PHARMA CO ORDINARY SHARES
GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.

Price reaction, T-5 to T+3

Ticker	T-5	T-3	T-1	T0	T+1	T+2	T+3
NAMS	—	—	—	—	—	—	—
ACHC	—	—	—	—	—	—	—
ASND	—	—	—	—	—	—	—
ATYR	—	—	—	—	—	—	—
BBIO	—	—	—	—	—	—	—
DVA	—	—	—	—	—	—	—

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

Source: BioPharma Dive

NewAmsterdam Pharma Co N.V (NAMS) since this story, compared with the market

Since the first closing price after “Xenon shares fall following depression trial pause,” NewAmsterdam Pharma Co N.V (NAMS) is -9.46%. The S&P 500 fund (SPY) is -0.89% over the same days, a -8.56% difference versus the market.

NAMS

SPY

Official trades in NewAmsterdam Pharma Co N.V (NAMS) around 18 Sep 2026

Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 11 days after publication, inside 30 days. The filing is listed beside the story “Xenon shares fall following depression trial pause.”

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around NewAmsterdam Pharma Co N.V (NAMS)

Companies mentioned with this story

NAMS NewAmsterdam Pharma Co N.V
For “Xenon shares fall following depression trial pause,” NewAmsterdam Pharma Co N.V (NAMS) is linked, with no stored direction, medium confidence. Reason on file: GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 18 Sep 2026 story “Xenon shares fall following depression trial pause.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 18 Sep 2026 story “Xenon shares fall following depression trial pause.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ATYR aTYR PHARMA
For “Xenon shares fall following depression trial pause,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
BBIO BridgeBio Pharma
For “Xenon shares fall following depression trial pause,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
DVA Davita
For “Xenon shares fall following depression trial pause,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

How “Xenon shares fall following depression trial pause” reaches NewAmsterdam Pharma Co N.V (NAMS)

The 18 Sep 2026 story “Xenon shares fall following depression trial pause” names NewAmsterdam Pharma Co N.V (NAMS) because of this story.

For NewAmsterdam Pharma Co N.V (NAMS), the reason on file says GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

The price range for NewAmsterdam Pharma Co N.V (NAMS), and the dates in the story

ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. NAMS traded between 19.58 and 25.10 across 20 sessions. The latest close on file is 20.49.

A simple score for NewAmsterdam Pharma Co N.V (NAMS)

46 out of 100

“Xenon shares fall following depression trial pause” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.